P

resident Trump’s promise to “slash the restraints” at the Food and Drug Administration appeared to lay down a marker for sweeping deregulation — and the Twittersphere reacted with both cheers and jeers.

During his address to a joint session of Congress on Tuesday night, Trump decried a “slow and burdensome” regulatory process that he said has too often delayed access to new treatments. He promised to bring about swift change. If there is an avalanche of new medicines, however, their manufacturers had better keep the costs in check, since Trump also vowed — without specifics — to bring down drug prices immediately. That particular bit of his speech drew a rare bipartisan standing ovation.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy